The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard Therapy

Official title

A Single-Center, Single-Arm, Phase II Clinical Trial of TROP2-ADC in Patients With Advanced Extrapulmonary High-Grade Neuroendocrine Tumors Refractory to Standard Therapy

Overview

The response rate to second-line or later therapies for extrapulmonary high-grade neuroendocrine neoplasms (NENs) remains low, with no established standard treatment regimen. Patients exhibit short survival periods, with median overall survival ranging from 5.1 to 18 months, representing a significant unmet clinical need. Sacituzumab govitecan has been evaluated in multiple clinical trials including OptiTROP-Breast01, KL264-01, OptiTROP-Lung01, OptiTROP-Lung03, and SKB264-Ⅱ-06. Current results consistently indicate promising efficacy of Sacituzumab govitecan in lung cancer, breast cancer, and cervical cancer. Notably, data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting revealed that TROP2 is highly expressed in neuroendocrine tumors, and its expression is significantly associated with poor prognosis. This suggests TROP2-directed antibody-drug conjugates (ADCs) may demonstrate promising therapeutic potential in NENs. Research Objective:To evaluate the efficacy of Sacituzumab govitecan in patients with advanced extrapulmonary neuroendocrine neoplasms who have progressed on standard therapies.

Interventions

• Drug Sac-TMT
  Sacituzumab govitecan 5 mg/kg every 2 weeks on Day 1 of each cycle（IV）

Primary outcome measures

• Objective Response Rate(ORR) [Time frame: 2 months]

Secondary outcome measures (3)

• Progression-Free Survival(PFS) [Time frame: 2 years]
• Disease Control Rate (DCR) [Time frame: 2 years]
• Overall Survival(OS) [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

• Provide written informed consent and voluntarily participate in the study.
• Aged 18-75 years, male or female.
• Histologically or cytologically confirmed diagnosis of one of the following:

Metastatic neuroendocrine carcinoma (NEC) Neuroendocrine tumor (NET) Grade 3 (G3) Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with >30% neuroendocrine component.

• Progression after at least one prior line of systemic therapy.
• ECOG Performance Status of 0 or 1.
• Life expectancy ≥3 months.
• At least one measurable lesion per RECIST 1.1 at baseline:
• Lesions must not have received prior local therapy (e.g., radiotherapy). Lesions within prior radiotherapy fields are acceptable if progression is documented.
• Adequate organ function (no blood products/growth factors within 14 days prior):

• Absolute neutrophil count (ANC) ≥1.5×10⁹/L

• Platelets ≥100×10⁹/L ③Hemoglobin ≥8 g/dL ④Total bilirubin ≤1.5 × ULN ⑤ALT/AST ≤2.5 × ULN (≤5 × ULN if liver metastases present) ⑥Serum creatinine ≤1.5 × ULN or creatinine clearance >60 mL/min (Cockcroft-Gault formula).

9\. Contraception requirements:

Females of childbearing potential:

Negative serum pregnancy test within 72 hours prior to dosing. Use highly effective contraception (e.g., IUD, oral contraceptives, condoms) during and for ≥3 months after last dose.

Males with fertile partners:

Use effective contraception during and for ≥3 months after last dose.

Exclusion criteria

• (1) Active CNS metastases and/or carcinomatous meningitis.

• Exception: Subjects with treated brain metastases may enroll if: Stable for ≥28 days prior to study initiation, Off steroids for brain metastases ≥28 days. Note: Carcinomatous meningitis excluded regardless of stability.

(2) Major surgery, open biopsy, or significant trauma within 28 days prior to first dose.

(3) History of severe interstitial lung disease (ILD) with inadequate control. (4) Uncontrolled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg despite antihypertensive therapy).

(5) Poorly controlled cardiovascular disease, including:

• NYHA Class II+ heart failure
• Unstable angina
• Myocardial infarction within 1 year
• Clinically significant supraventricular/ventricular arrhythmias refractory to intervention (6) Clinically significant bleeding within 3 months prior to first dose (e.g., GI bleeding, hemorrhagic gastric ulcer, vasculitis). (7) Arterial/venous thromboembolic events within 6 months prior to first dose (e.g., CVA, TIA, cerebral hemorrhage, DVT, PE).Exception: Superficial thrombosis per investigator assessment.

(8) Active other malignancy requiring therapy. Exceptions: Non-melanoma skin cancer in situ with curative treatment.

(9)Pregnancy or lactation. (10)Other factors potentially leading to premature discontinuation per investigator judgment: Severe comorbidities (including psychiatric), Critical lab abnormalities, Social/familial factors compromising safety/data integrity (11)TROP2-targeted agents, ADC drugs (e.g., 8201)Topoisomerase I inhibitor-containing ADCs (12)Live vaccination within 30 days prior to first dose or planned during study.

(13)Requirement for strong CYP3A4 inhibitors/inducers within 2 weeks prior to first dose or during study.

(14) Palliative radiotherapy to known metastatic sites within 2 weeks prior to first dose.

(15)Systemic anti-infective therapy within 1 week prior to first dose. Severe ocular conditions including: (16)Dry eye syndrome, Meibomian gland dysfunction, Blepharitis, Corneal disease delaying healing (17)Other exclusionary conditions per investigator assessment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07077564 · 2025-0615

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗